Compare Consolidated Edison, Inc. (ED) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Consolidated Edison, Inc. vs TG Therapeutics Inc — how do they compare? Consolidated Edison, Inc. trades at $107.51 (market cap $39.76B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Consolidated Edison, Inc. is far larger — about 5.2× TG Therapeutics Inc's market cap, and Consolidated Edison, Inc. pays a 3.27% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ED | TGTX | |
|---|---|---|
Market Cap | $39.76B | $7.64B |
Sector | Utilities | Health |
52-Week High | $115.46 | $59.06 |
52-Week Low | $95.37 | $26.94 |
Enterprise Value | $66.61B | $7.84B |
Dividend Yield | 3.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Consolidated Edison (ED) trades at $107.78, up 1.39% with mixed technical signals showing bearish moving averages but neutral oscillators. The utility company reported strong Q2 2026 earnings of $0.83 per share, beating estimates, with revenue growth driven by higher electric and gas rate bases. ED maintains a stable dividend yield with consistent quarterly payments of $0.89 and reaffirmed 2026 earnings guidance amid rising power demand from data centers.
ED offers defensive exposure with predictable returns supported by its regulated monopoly, but faces execution risks from grid upgrades and interest rate sensitivity. Analyst consensus is cautious with 63% hold ratings and a $103.25 price target below current levels, suggesting limited near-term upside despite solid fundamentals and growing power demand trends.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Consolidated Edison, Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.
Read more on ED →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
